Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Revinty Ellipta

- PMLiVE

AZ gets US approval for diabetes combo Qtern

Wins licensing for Onglyza/Farxiga dual-therapy after rejection by the FDA in 2015

- PMLiVE

J&J gets CHMP backing for broader Darzalex use

Recommendation for earlier-stage approval could see multiple myeloma drug reach blockbuster sales

- PMLiVE

AZ nears EU approval for hyperkalaemia drug Lokelma

CHMP adopts positive opinion for the potassium-binding treatment

- PMLiVE

Mundipharma to launch first MabThera biosimilar in EU

EMA approves Truxima in all indications licensed to Roche’s cancer drug

Roche Basel Switzerland

Roche’s lung cancer drug Alecensa wins EU approval

Monotherapy conditionally approved as second-line NSCLC treatment

Eli Lilly HQ

Lilly claims first place for JAK inhibitor Olumiant in EU

EMA approves once-daily rheumatoid arthritis drug ahead of Pfizer’s Xeljanz

- PMLiVE

Denmark pitches for EMA, with help from ex Novo Nordisk CEO

Lars Rebien Sørensen to serve as special envoy to promote Danish candidacy

- PMLiVE

Amgen’s Humira biosimilars backed for EU approval

Amgevita and Solymbic prepare to challenge AbbVie’s blockbuster

- PMLiVE

Brexit – a tough pill to swallow

What will be expected of the UK when the post-Brexit environment takes shape?

Eli Lilly HQ

Lilly nears EU approval of arthritis drug baricitinib

On course for early 2017 verdict, setting up challenge to Pfizer’s Xeljanz

- PMLiVE

Intercept gets EU nod for rare liver disease therapy

Ocaliva approved as a combination treatment for primary biliary cholangitis

- PMLiVE

New Jardiance label could boost sales by $1.7bn, says analyst

Diabetes treatment can reduce the risk of cardiovascular death in type 2 patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links